Neurogenic orthostatic hypotension (nOH) occurs when the body loses the ability to regulate blood pressure as a person moves from sitting to standing. Upon standing, some people living with multiple system atrophy (MSA) experience a sudden drop in blood pressure. This can cause dizziness, lightheadedness, and feeling faint or like you might blackout. These symptoms caused by drops in blood pressure are called symptomatic nOH.

Theravance Biopharma is looking for volunteers to take part in the Phase 3 CYPRESS clinical research study (NCT05696717) to look at whether an investigational drug, called ampreloxetine, works and how safe it is when taken over several months to treat symptomatic neurogenic orthostatic hypotension (symptomatic nOH) in people with multiple system atrophy (MSA). 

The primary assessments will determine whether the investigational drug can improve the symptoms of nOH.

If you have MSA, are over 30 years old, and experience dizziness, lightheadedness, feeling faint, or like you might blackout, then you may be eligible to participate. If you qualify and join the study, participation will last approximately six months, followed by an optional 2-year long-term extension in which all participants will receive the investigational drug. Participants may be eligible to participate in the study remotely (e.g., from your home) after an initial in-office study visit.